PICO question and search strategy
Patient: Equines undergoing diagnostic analgesia for lameness evaluation. Intervention: a 2 agonists. Comparison: Use of a 2 agonists compared with none. Outcome: Accuracy in diagnosis of lameness improvement. CAB abstracts were searched using the following terms: (Equine*/Horse*/Equus*/Foal*/Colt*) AND (Alpha-2 Agonists*/ Alpha-2 Adrenergic Agonist*). Of 79 results, screening was based on the title and abstract in regards to question relevancy. Although all addressed use of a 2 agonists in equines and illustrated the major pharmacology of a 2 agonists, none reported use of sedation in equine lameness exams. A further screen on PubMed (using Equine* AND Lameness* AND Sedation*) obtained three relevant results.
Results

Buchner et al. (1999)
Although a relatively dated article, the paper set out to evaluate the locomotion patterns in both sound and lame horses after administering detomidine and antagonising with atipamezole prior to lameness assessment. In total, 17 horses (nine sound, eight chronically forelimb lame) were used in the study, with a repeated measures design. Horses were seen trotting on a treadmill at various time points post-sedation, focusing particularly on stride length and hoof movements in the forelimbs. Level of sedation was based on heart rate and head height. The same exercise was performed the following day; with sedation being antagonised with atipamezole after 15 min. Results showed that detomidine-sedated horses at 15 min develop a longer stride length, which could be reversed with atipamezole. The authors report no difference in perceived lameness using a head acceleration asymmetry system, and when using a 2 antagonists, there was no relapse into sedation. The authors suggest that detomidine administration does not decrease the lameness grade, but does change the locomotor pattern. This may make assessment of response to diagnostic analgesia difficult in mild cases. Additionally, a 2 antagonists may be useful, but can be expensive.
Rettig et al. (2016)
A more recent article evaluated the effects of low dose xylazine on fore-and hindlimb lameness by using body mounted inertial sensors. In total, 44 horses of various comfort levels were divided into xylazine treatment and saline control groups. Degree of sedation was assessed by head height and ataxia grade. Horses were then assessed on a straight line, focusing on vertical head height and vertical pelvic movement asymmetry. There was no significant difference in head movement and pelvic movement asymmetry between time 0 and 20 min, and time 0 and 60 min in both treatment groups. Although, some horses with forelimb lameness changed their lameness grade, this was not significant between treatments. This was not the case with hindlimb lameness. This study provided some supportive evidence that the use of a 2 agonists does not mask lameness.
Da Silva Azevedo et al. (2015)
This study had a similar protocol to Rettig et al. using inertial sensors, but compared the difference between xylazine and acepromazine in lameness evaluation. Interestingly, no analgesic effect of xylazine was found at low doses, with no significant difference in lameness before and after xylazine.
Can this evidence be applied to my clinical scenario?
All studies (Buchner et al. 1999; Da Silva Azevedo et al. 2015; Rettig et al. 2016) provide support for a 2 agonists use in lameness investigations, although the long action of effect with detomidine may prevent its use in fast-acting nerve and synovial blocks (Clarke et al. 2014) . The use of short-acting xylazine does not appear to mask lameness, although, care must be taken in interpreting diagnostic analgesia in mild forelimb lameness after sedation.
Further questions raised?
During the appraisal, a few questions were raised, including ridden assessment of horses after sedation with a 2 agonist, opioid combinations and the potential side effects of a 2 antagonists. Moreover, the possibility of species variation in the pharmacology of a 2 agonists, which was raised, has some evidence (Latzel 2012 ).
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